Lasts Longer than Any Other Dermal Filler on the Market Today

(Livingston, NJ) On August 24, 2006, the Food and Drug Administration (FDA)
recommended the clearance of RadiesseT, a next-generation soft tissue
augmentation product for use as a filler material to restore soft tissue
facial contours. RadiesseT differs from all other injectables on the market
today. For one, it lasts more than twice as long, averaging 12-18 months. [more]

By Julie Kahn N.D. L.Ac. M.S. M.S.AOm.

Millions of Americans and over a billion people world wide use acupuncture and Chinese herbal medicine. Why? Because they WORK!

Acupuncture has developed as an art and science in China for at least 5,000 years. As more research has verified the effectiveness of acupuncture and Chinese herbal medicine, and more people have sought medical alternatives, the popularity of this energetic medicine has dramatically increased. [more]

By Koren Barrett, N.D.

There are many substances used in common cosmetic products that have been shown to be harmful to our health. Beauty products are absorbed through the skin into the bloodstream where they can reach many parts of our bodies. A recent study reported by the environmental working group found that the average adult used nine cosmetic products daily and more than 25% of women used 15 or more. This gives us ample opportunity for exposure to chemicals contained in those products. We will discuss 2 of the most concerning chemicals. [more]

Syneron Finance is offering a new deal to potential customers. Effective immediately, the company is offering no payments, no interest on Syneron equipment until January 1, 2008.

In January 2008, the customer will have a one-time option to pay off the agreement for the original sales price plus taxes due. If the customer does not pay off in January 2008, they will pay 36 monthly payments at a rate factor of .03321. At the end of the 51 month term, the customer will own the equipment for $1.00. This agreement qualifies for TAX CODE 179 accelerated depreciation. [more]

Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, announced the appointment of Stephen May, 44, to the newly created position of Senior Vice President of Global Marketing.

“We are pleased to have Stephen join the Cynosure management team,” said Chief Executive Officer Michael R. Davin. “With more than 14 years of direct sales and marketing experience in the aesthetic laser industry, he brings an impressive track record, especially in the areas of branding and new product introductions. His background aligns with our growth strategy, including expanding our international market presence. We believe he will be a valuable asset to us going forward.”
[more]

Candela Corporation (NASDAQ: CLZR), a global leader in the development and commercialization of advanced aesthetic laser and light based systems, announced that it has filed a complaint against Palomar Medical Technologies, Inc. (NASDAQ: PMTI) in the United States District Court for the District of Massachusetts. [more]

Palomar Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, announced that it filed a lawsuit in the U.S. District Court for the District of Massachusetts against Candela Corporation (Nasdaq: CLZR) for patent infringement. In this lawsuit, Palomar has accused Candela’s light-based hair removal systems, including the GentleLase and GentleYag, of infringing U.S. Patent No. 5,735,844 (”the ‘844 Patent”). Palomar has an exclusive license to the ‘844 Patent from the General Hospital Corporation in Boston, Massachusetts. The patent claims asserted against Candela in this lawsuit include the same claims that Palomar successfully asserted against Cutera, Inc. (Nasdaq: CUTR) as well as additional patent claims. [more]

Cutera Sets New Record for Revenue, and Raises Full-Year Guidance
Cutera, Inc. (Nasdaq: CUTR), a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, reported financial results for the second quarter and six months ended June 30, 2006. Key financial highlights are as follows: [more]

New product with optimized spot size and advanced dosage control expands Fraxel family of laser products

Mountain View, CA – August 14, 2006 - Reliant Technologies, Inc. today announced the launch of the Fraxel SR1500 laser, the latest innovation in aesthetic laser medical technology. The Fraxel SR1500 laser combines proprietary advancements in optical technology with medical software offering physicians a treatment option that penetrates up to 30 percent deeper, delivering consistent dosage control and optimizing lesion depths. This leap in technology provides patients a safe and effective, non-invasive treatment option for skin conditions ranging from mild sun damage to severe acne scarring. [more]